Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | Assessing the future of radiopharmaceuticals in kidney cancer

Eric Jonasch • 15 Feb 2025

GU Cancers 2025

Genitourinary Cancer Kidney Cancer

Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the emerging role of radiopharmaceuticals in the treatment landscape for renal cell carcinoma. The exact role of these agents remains to be elucidated, with many questions to be answered regarding delivery, targeting, doses, and schedules. Whilst the field is behind that of prostate cancer, there are many potential benefits of these therapies. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.